Diabetes - BioPharmChina

Illustration of topical gel applied to a diabetic foot ulcer, with magnified tissue and a bank and coins representing Medinno’s financing.

Medinno Raises More Than RMB 200 Million to Advance Topical Drug for Diabetic Foot Ulcers

By Henry Tseng

2 Min Read

Medinno has raised more than RMB 200 million in a Series A financing led by Sunshine Ronghui Capital, giving the company fresh funding to develop MDI-1228, a topical drug candidate for diabetic foot ulcers and other conditions. The proceeds will support…

Illustration of Innovent Biologics’ IBI3042, a once-weekly oral GLP-1 receptor agonist, showing oral absorption, GLP-1 receptor activation and potential effects on weight loss, blood glucose and appetite.

Innovent’s Once-Weekly Oral GLP-1 IBI3042 Gets NMPA IND Clearance for Obesity

By Henry Tseng

No Comments

6 Min Read

Innovent Biologics has received clearance from China’s National Medical Products Administration (NMPA) to begin clinical development of IBI3042, a potentially first-in-class once-weekly oral small-molecule GLP-1 receptor agonist, marking another…